|
1
|
Vose J, Armitage J and Weisenburger D;
International T-Cell Lymphoma Project. International peripheral
T-cell and natural killer/T-cell lymphoma study: pathology findings
and clinical outcomes. J Clin Oncol. 26:4124–4130. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mourad N, Mounier N, Brière J, Raffoux E,
Delmer A, Feller A, Meijer CJ, Emile JF, Bouabdallah R, Bosly A,
Diebold J, Haioun C, Coiffier B, Gisselbrecht C and Gaulard P;
Groupe d’Etude des Lymphomes de l’Adulte. Clinical, biologic, and
pathologic features in 157 patients with angioimmunoblastic T-cell
lymphoma treated within the Groupe d’Etude des Lymphomes de
l’Adulte (GELA) trials. Blood. 111:4463–4470. 2008.PubMed/NCBI
|
|
3
|
de Leval L, Gisselbrecht C and Gaulard P:
Advances in the understanding and management of angioimmunoblastic
T-cell lymphoma. Br J Haematol. 148:673–689. 2010.PubMed/NCBI
|
|
4
|
Gallamini A, Zaja F, Patti C, Billio A,
Specchia MR, Tucci A, Levis A, Manna A, Secondo V, Rigacci L, et
al: Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line
treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo
Italiano Terapie Innovative nei Linfomi) prospective multicenter
trial. Blood. 110:2316–2323. 2007. View Article : Google Scholar
|
|
5
|
d’Amore F, Radford J, Relander T, Jerkeman
M, Tilly H, Osterborg A, Morschhauser F, Gramatzki M, Dreyling M,
Bang B and Hagberg H: Phase II trial of zanolimumab (HuMax-CD4) in
relapsed or refractory non-cutaneous peripheral T cell lymphoma. Br
J Haematol. 150:565–573. 2010.PubMed/NCBI
|
|
6
|
Dang NH, Pro B, Hagemeister FB, Samaniego
F, Jones D, Samuels BI, Rodriguez MA, Goy A, Romaguera JE,
McLaughlin P, et al: Phase II trial of denileukin diftitox for
relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol.
136:439–447. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
O’Connor OA, Pro B, Pinter-Brown L,
Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ,
Shustov AR, Gisselbrecht C, et al: Pralatrexate in patients with
relapsed or refractory peripheral T-cell lymphoma: results from the
pivotal PROPEL study. J Clin Oncol. 29:1182–1189. 2011.
|
|
8
|
Piekarz RL, Frye R, Prince HM, Kirschbaum
MH, Zain J, Allen SL, Jaffe ES, Ling A, Turner M, Peer CJ, et al:
Phase 2 trial of romidepsin in patients with peripheral T-cell
lymphoma. Blood. 117:5827–5834. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Advani R, Horwitz S, Zelenetz A and
Horning SJ: Angioimmunoblastic T cell lymphoma: treatment
experience with cyclosporine. Leuk Lymphoma. 48:521–525. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gottardi M, Danesin C, Canal F, Dei Tos
AP, Stefani PM, Calistri E, Salvadori U and Gherlinzoni F: Complete
remission induced by thalidomide in a case of angioimmunoblastic
T-cell lymphoma refractory to autologous stem cell transplantation.
Leuk Lymphoma. 49:1836–1838. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Arkenau HT, Chong G, Cunningham D, Watkins
D, Sirohi B, Chau I, Wotherspoon A, Norman A, Horwich A and Matutes
E: Gemcitabine, cisplatin and methylprednisolone for the treatment
of patients with peripheral T-cell lymphoma: the Royal Marsden
Hospital experience. Haematologica. 92:271–272. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee J, Suh C, Kang HJ, Ryoo BY, Huh J, Ko
YH, Eom HS, Kim K, Park K and Kim WS: Phase I study of proteasome
inhibitor bortezomib plus CHOP in patients with advanced,
aggressive T-cell or NK/T-cell lymphoma. Ann Oncol. 19:2079–2083.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl
Bancroft C, Sausville E, Adams J, Elliott P and Van Waes C: Novel
proteasome inhibitor PS-341 inhibits activation of nuclear
factor-kappa B, cell survival, tumor growth, and angiogenesis in
squamous cell carcinoma. Clin Cancer Res. 7:1419–1428.
2001.PubMed/NCBI
|
|
14
|
Zhao WL, Liu YY, Zhang QL, Wang L, Leboeuf
C, Zhang YW, Ma J, Garcia JF, Song YP, Li JM, et al: PRDM1 is
involved in chemoresistance of T-cell lymphoma and down-regulated
by the proteasome inhibitor. Blood. 111:3867–3871. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shi WY, Wang L, Xiao D, Yao Y, Yang F,
Jiang XX, Leboeuf C, Janin A, Chen SJ and Zhao WL: Proteasome
inhibitor bortezomib targeted tumor-endothelial cell interaction in
T-cell leukemia/lymphoma. Ann Hematol. 90:53–58. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Martínez-Delgado B, Cuadros M, Honrado E,
Ruiz de la Parte A, Roncador G, Alves J, Castrillo JM, Rivas C and
Benítez J: Differential expression of NF-kappaB pathway genes among
peripheral T-cell lymphomas. Leukemia. 19:2254–2263.
2005.PubMed/NCBI
|
